Galapagos, Merck in Potential €170M Obesity, Diabetes Deal
Mechelen, Belgium-based Galapagos NV signed its fifth major pharmaceutical alliance, inking a potential €171.5 million (US$230.4 million)-plus deal with Merck & Co. Inc. to develop drugs aimed at the obesity and diabetes markets.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter